Design and characterization of a consensus hemagglutinin vaccine immunogen against H3 influenza A viruses of swine

Sun, Hanjun; Sur, Jung Hyang; Sillman, Sarah; Steffen, David; Vu, Hiep L.X.

doi:10.1016/j.vetmic.2019.108451

Cited by 7 publications

(13 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sun H., et al. recently described the utility of a consensus vaccine immunogen against H3 IAV-S HA protein (H3-CON.1) ( Sun et al., 2019 ). Analysis of several genetically diverse IAV-S H3 strains demonstrated that the consensus immunogen induced significantly higher cross-reactive antibody and T cell responses compared to a wildtype HA (H3-TX98).…”

Section: Novel Experimental Vaccines Against Iav-smentioning

confidence: 99%

“…The approach aims to decrease the genetic distance between the vaccine and circulating field strains by creating a synthetic immunogen that is representative of a diverse population of sequences. Sun H., et al recently described the utility of a consensus vaccine immunogen against H3 IAV-S HA protein (H3-CON.1) (Sun et al, 2019). Analysis of several genetically diverse IAV-S H3 strains demonstrated that the consensus immunogen induced significantly higher cross-reactive antibody and T cell responses compared to a wildtype HA (H3-TX98).…”

Section: Consensus Designmentioning

confidence: 99%

See 1 more Smart Citation

Swine influenza A virus: challenges and novel vaccine strategies

Petro-Turnquist,

Pekarek,

Weaver

2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Swine Influenza A Virus (IAV-S) imposes a significant impact on the pork industry and has been deemed a significant threat to global public health due to its zoonotic potential. The most effective method of preventing IAV-S is vaccination. While there are tremendous efforts to control and prevent IAV-S in vulnerable swine populations, there are considerable challenges in developing a broadly protective vaccine against IAV-S. These challenges include the consistent diversification of IAV-S, increasing the strength and breadth of adaptive immune responses elicited by vaccination, interfering maternal antibody responses, and the induction of vaccine-associated enhanced respiratory disease after vaccination. Current vaccination strategies are often not updated frequently enough to address the continuously evolving nature of IAV-S, fail to induce broadly cross-reactive responses, are susceptible to interference, may enhance respiratory disease, and can be expensive to produce. Here, we review the challenges and current status of universal IAV-S vaccine research. We also detail the current standard of licensed vaccines and their limitations in the field. Finally, we review recently described novel vaccines and vaccine platforms that may improve upon current methods of IAV-S control.

show abstract

Section: Novel Experimental Vaccines Against Iav-smentioning

confidence: 99%

Section: Consensus Designmentioning

confidence: 99%

Swine influenza A virus: challenges and novel vaccine strategies

Petro-Turnquist,

Pekarek,

Weaver

2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The blood tubes were then centrifuged at 1200× g for 15 min, and the plasma was collected and stored at −20 • C for the evaluation of humoral immune responses. The cells were resuspended in PBS and peripheral blood mononuclear cells (PBMCs) were collected and washed twice with PBS containing 2% FBS as described before [21]. The cells were then suspended in a cell-freezing medium containing 50% RPMI, 40% FBS, and 10% DMSO and then cryopreserved for the evaluation of T-cell responses.…”

Section: Animal Experimentsmentioning

confidence: 99%

“…Virus-infected cells were detected in lung and trachea sections using the RNA in situ hybridization (ISH) assay as previously described [21]. The frequency of virus-infected cells in airway epithelium and pulmonary parenchyma was estimated for each lung component using a 5-point scale: 0-no signals, 1-minimal occasional signals, 2-mild scattered signals, 3-moderate scattered signals, and 4-abundant signals.…”

Section: Pathological Analysismentioning

confidence: 99%

See 1 more Smart Citation

A Single-Dose Intramuscular Immunization of Pigs with Lipid Nanoparticle DNA Vaccines Based on the Hemagglutinin Antigen Confers Complete Protection against Challenge Infection with the Homologous Influenza Virus Strain

Nguyen,

Kumari,

Sillman

et al. 2023

Vaccines

Self Cite

View full text Add to dashboard Cite

The Influenza A virus of swine (IAV-S) is highly prevalent and causes significant economic losses to swine producers. Due to the highly variable and rapidly evolving nature of the virus, it is critical to develop a safe and versatile vaccine platform that allows for frequent updates of the vaccine immunogens to cope with the emergence of new viral strains. The main objective of this study was to assess the feasibility of using lipid nanoparticles (LNPs) as nanocarriers for delivering DNA plasmid encoding the viral hemagglutinin (HA) gene in pigs. The intramuscular administration of a single dose of the LNP-DNA vaccines resulted in robust systemic and mucosal responses in pigs. Importantly, the vaccinated pigs were fully protected against challenge infection with the homologous IAV-S strain, with only 1 out of 12 vaccinated pigs shedding a low amount of viral genomic RNA in its nasal cavity. No gross or microscopic lesions were observed in the lungs of the vaccinated pigs at necropsy. Thus, the LNP-DNA vaccines are highly effective in protecting pigs against the homologous IAV-S strain and can serve as a promising platform for the rapid development of IAV-S vaccines.

show abstract